Guillaume Noell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guillaume Noell has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alvar Agustí
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
1 shared publication - Amanda Iglesias
Institut d’Investigació Sanitària Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain
1 shared publication - Andreas Jahn
Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa), Palma De Mallorca, Spain
1 shared publication - Angel Rios
Department of Respiratory Medicine, Hospital Universitari Son Espases-IdISBa, Valldemossa 79, 07010, Palma de Mallorca, Spain
1 shared publication - Borja Garcia Cosío
Son Espases University Hospital, IdISBa, Ciberes, Mallorca, Spain
1 shared publication - Julio Iglesias
Department of Immunology, University Hospital Son Espases, Palma de Mallorca, Spain
1 shared publication
Latest Publications
- Open Access
- 15 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 1-9
Bone marrow characterization in COPD: a multi-level network analysis
Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair. Yet, BM composition has not been previously characterized in COPD patients. In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8) and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network correlation analysis. We found that: (1) there were no major significant pair wise differences between COPD patients and controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies a relation between immunity, repair and lung function not previously described, that remains in the COPD network but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity and repair, particularly in patients with emphysema. Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients with more emphysema and/or higher circulating eosinophils.
- 15 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 1-9
Open AccessBone marrow characterization in COPD: a multi-level network analysis
Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair. Yet, BM composition has not been previously characterized in COPD patients. In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8) and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network correlation analysis. We found that: (1) there were no major significant pair wise differences between COPD patients and controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies a relation between immunity, repair and lung function not previously described, that remains in the COPD network but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity and repair, particularly in patients with emphysema. Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients with more emphysema and/or higher circulating eosinophils.